IQVIA

IQV

Market cap $30.3B

IQVIA Holdings delivered strong Q4 and full-year 2025 results, confirming its leadership in data, analytics, and clinical execution. Despite macro headwinds and cautious biotech spending, IQV maintained robust profitability, near-100% cash conversion, and expanded its $32.7B backlog. EPS guidance for 2026 was below consensus, triggering a selloff, but I remain bullish due to durable bookings, backlog, and elite financial metrics.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today published its 2025 Sustainability Report. The report highlights IQVIA's progress across its People, Public and Planet pillars, consistent with the company's mission to accelerate innovation for a healthier world. IQVIA's 2025 Sustainability Report can be downl.

IQVIA Holdings Inc. (IQV) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day Transcript

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced it has entered into an agreement to acquire certain discovery services assets from Charles River Laboratories. These assets include five sites specializing in a range of in vitro drug discovery services, including established laboratory based New Approach Metho.

Analysts expect these stocks to soar at least 46% over the next 12 months.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that Ron Bruehlman, chief financial officer, and Mike Fedock, senior vice president, financial planning & analysis and incoming CFO, will speak at Citi's 2026 Unplugged MedTech and Life Sciences Access Day on Thursday, February 26, 2026,.

Explore IQVIA's (IQV) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Investors need to pay close attention to IQVIA stock based on the movements in the options market lately.

Oakmark Global All Cap Strategy portfolio's return was 4.99% (net) for the reporting period vs. MSCI World Index that returned 3.12% for the same period. Contributors in the quarter were DSV, IQVIA Holdings and Samsung Electronics Pfd. Detractors in the quarter were Alibaba Group, CNH Industrial and Dassault Systemes.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, and the Duke Clinical Research Institute (DCRI), one of the world's largest academic clinical research organizations with extensive experience designing and operationally executing large, complex multi-center clinical trials, are pleased to announce their new collaboration to enha.